Mexico Generic Drugs Market: Industry Analysis and Forecast (2024-2030)

  • The Mexico Generic Drugs Market size was valued at USD 690 Million in 2023 and the total Mexico Generic Drugs revenue is expected to grow at a CAGR of 9.8% from 2024 to 2030, reaching nearly USD 1320 Million.

  • Format : PDF | Report ID : SMR_1611

Generic drugs, bioequivalent to brand-name counterparts, offer cost-effective alternatives post-patent expiry. Rigorously tested for quality and safety, they improve healthcare accessibility and affordability. The Mexico Generic Drugs Market availability and affordability drive market growth and expired patents contribute significantly. In rising healthcare costs, payers and providers promote generics for cost containment. The government initiatives and incentives added encourage their use, fostering a positive market outlook. The aging population and patent expirations for blockbuster drugs create additional growth opportunities for generic manufacturers, influencing the Mexico Generic Drugs market dynamics positively.


  • In 2023, Mexico imported approximately $XXX million worth of generic drugs, Key imports include antibiotics, antihypertensives, and antidiabetics.
  • Mexico likely exported $XXX million in generic drugs, signaling potential growth from 2022. Key destinations include Guatemala, Colombia, and Costa Rica in Central and South America, with significant exports to the United States. The top exported drugs are antibiotics, antihypertensives, and antidiabetics.


The comprehensive report covers a detailed analysis of the Mexico Generic Drugs Market. STELLAR has precisely examined the industry's evolution, spotlighting significant trends, groundbreaking innovations, and the driving forces that mold its trajectory. Delving deep into the present landscape, the report dissects the Mexico Generic Drugs Market. It accurately outlines the market's current dimensions, growth patterns, size, and the nuanced trends that use significant influence. Additionally, it keenly identifies the pivotal factors driving market growth and sheds light on growing opportunities.


Mexico Generic Drugs Market


Increasing Demand for Chronic Disease Management to Drives the Generic Drugs Market in Mexico


The Mexico generic drugs market is experiencing significant growth thanks to the rising demand for affordable medications to manage chronic diseases. The surge has attracted investments in local production and distribution, thereby fostering economic growth and creating job opportunities. The increased availability of generic drugs not only improves accessibility and affordability for patients with chronic conditions but also improves their quality of life and health outcomes, reducing the strain on the healthcare system and promoting social equity.


The increasing Mexico generic drugs market catalyzes manufacturers to invest in research and development, driving innovation in the production of tailored generic drugs that cater to the specific needs of Mexican patients and fostering technological advancements within the local pharmaceutical industry. Additionally, efforts towards regulatory harmonization between Mexico and other countries are underway to meet the growing demand, facilitating trade and providing access to a broader range of generic drugs, ultimately streamlining processes and reducing costs for both patients and manufacturers. The market's growth not only addresses healthcare needs but also contributes to job creation, particularly in manufacturing, distribution, and healthcare sectors, thereby fostering economic development, skills enhancement, and ultimately improving the standard of living and reducing poverty.


Mexico Generic Drugs Market


The Mexico generic drugs market's rapid growth increases concerns about quality control and counterfeit drugs, posing risks to patient health and undermining industry trust. Affordability-driven overreliance on generic drugs impedes investment in innovative treatments, constraining long-term healthcare progress. The Market price wars compromise quality standards, impacting employee well-being and sustainability. Unethical marketing targeting vulnerable patients results in overmedication, worsening healthcare disparities. The increasing pharmaceutical production raises environmental concerns, demanding the implementation of sustainable practices to minimize the impact on the environment.


Mexico Generic Drugs Market Segment Analysis


Based on Product, the Simple Generics segment held the largest market share of about 75% in the Mexico Generic Drugs Market in 2023. According to the STELLAR analysis, the segment is expected to grow at a CAGR of 9.9% during the forecast period. It stands out as the dominant segment within the Mexico Generic Drugs Market thanks to its rapid technological advancement and growing adoption of smart devices with data connectivity and integration.


Mexico Generic Drugs Market


The Mexico Generic Drugs Market increased the affordability and accessibility of generic drugs, often than their branded counterparts, and widened access to crucial medications, particularly for those on fixed incomes. Enhanced competition, stemming from multiple manufacturers producing the same generic drug, drives down prices, fostering cost-effectiveness and compelling branded drug makers to lower their prices. Lower costs also contribute to improved medication adherence, resulting in better health outcomes and reduced long-term healthcare expenses. Additionally, the availability of simple generics across various therapeutic areas ensures a broad range of treatment options for patients dealing with common ailments and chronic conditions.


The importance of low-cost, simple generics impedes investment in research for innovative drugs, particularly for complex or rare diseases, hindering progress in treating challenging medical conditions. Quality concerns persist, as variations in manufacturing processes, inactive ingredients, or drug delivery systems potentially impact generic drug quality compared to branded drugs. Intense competition in the simple Mexico Generic Drugs market leads to market consolidation, with a few large manufacturers dominating, reducing competition and potentially granting these manufacturers more power to increase prices. Generic drug manufacturing carries environmental consequences, including resource use and waste generation, emphasizing the need to incorporate sustainable practices to minimize the industry's environmental footprint.


Mexico Generic Drugs Market Scope

Market Size in 2023

USD 690 Million

Market Size in 2030

USD 1320 Million

CAGR (2024-2030)


Historic Data


Base Year


Forecast Period


Segment Scope

By Product

  • Simple Generics
  • Super Generics
  • Biosimilars

By Application

  • Cardiovascular Products
  • Anti-Infective Drugs
  • Anti-Arthritis Drugs
  • Central Nervous System Drugs
  • Anti-Cancer Drug
  • Respiratory Products

By Distribution Channel

  • Hospitals
  • Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies


Leading Key Players in the Mexico Generic Drugs Market

  • Farmacias Benavides
  • Grupo Saba
  • Genomma Lab
  • Apotex
  • Teva Pharmaceuticals
  • Mylan
  • Sandoz
  • PiSA Farmacéutica
  • Laboratorios Sophia
  • Grupo Bruluart

Frequently Asked Questions

Ans. Increasing Demand for Chronic Disease Management is expected to be the major driver for the Mexico Generic Drugs market.

1.    Mexico Generic Drugs Market Executive Summary

1.1 Study Assumption and Market Definition
1.2 Scope of the Study
1.3 Emerging Technologies
1.4 Market Projections
1.5 Strategic Recommendations

2.    Mexico Generic Drugs Market Import Export Landscape
2.1 Import Trends
2.2 Export Trends
2.3 Regulatory Compliance
2.4 Major Export Destinations
2.5 Import-Export Disparities

3.    Mexico Generic Drugs Market Trends
3.1 Market Consolidation
3.2 Adoption of Advanced Manufacturing Technologies
3.3 Pricing and Reimbursement Trends

4.    Mexico Generic Drugs Market: Dynamics
4.1.1 Market Driver
4.1.2 Market Restraints
4.1.3 Market Opportunities
4.1.4 Market Challenges

4.2 PORTER’s Five Forces Analysis
4.3 PESTLE Analysis
4.4 Regulatory Landscape 
4.5 Analysis of Government Schemes and Initiatives for the Mexico Generic Drugs Industry
4.6 The Pandemic and Redefining of The Mexico Generic Drugs Industry Landscape

5.    Mexico Generic Drugs Market: Market Size and Forecast by Segmentation (Value) (2023-2030)
5.1 Mexico Generic Drugs Market Size and Forecast, by Product (2023-2030)
5.1.1 Simple Generics
5.1.2 Super Generics
5.1.3 Biosimilars

5.2 Mexico Generic Drugs Market Size and Forecast, Application (2023-2030)
5.2.1 Cardiovascular Products
5.2.2 Anti-Infective Drugs
5.2.3 Anti-Arthritis Drugs
5.2.4 Central Nervous System Drugs
5.2.5 Anti-Cancer Drug
5.2.6 Respiratory Products

5.3 Mexico Generic Drugs Market Size and Forecast, Distribution Channel (2023-2030)
5.3.1 Hospitals
5.3.2 Pharmacies
5.3.3 Private Clinics
5.3.4 Drug Stores
5.3.5 Retail Pharmacies

5.4 Mexico Generic Drugs Market: Competitive Landscape
5.5 STELLAR Competition Matrix
5.6 Competitive Landscape
5.7 Key Players Benchmarking
5.7.1 Company Name
5.7.2 Service Segment
5.7.3 End-user Segment 
5.7.4 Revenue (2023)
5.7.5 Company Locations

5.8 Leading Mexico Generic Drugs Companies, by market capitalization
5.9 Market Structure
5.9.1 Market Leaders 
5.9.2 Market Followers
5.9.3 Emerging Players

5.10 Mergers and Acquisitions Details

6.    Company Profile: Key Players
6.1 Farmacias Benavides
6.1.1 Company Overview
6.1.2 Business Portfolio
6.1.3 Financial Overview
6.1.4 SWOT Analysis
6.1.5 Strategic Analysis
6.1.6 Scale of Operation (small, medium, and large)
6.1.7 Details on Partnership
6.1.8 Regulatory Accreditations and Certifications Received by Them
6.1.9 Awards Received by the Firm
6.1.10  Recent Developments

6.2 Grupo Saba
6.3 Genomma Lab
6.4 Apotex
6.5 Teva Pharmaceuticals
6.6 Mylan
6.7 Sandoz
6.8 PiSA Farmacéutica
6.9 Laboratorios Sophia
6.10 Grupo Bruluart

7.    Industry Recommendations

8.    Terms and Glossary

9.    Mexico Generic Drugs Market: Research Methodology

Enquiry Before Buy

Request Sample PDF